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New scoring system to create a prognostic criteria in colorectal
carcinoma based on serum elevation of C-reactive protein 
and decrease in lymphocyte in peripheral blood
Tadahiro Nozoe, Mayuko Kono, Sosei Kuma, Eiji Tsujita, and Takefumi Ohga 
Department of Surgery, Fukuoka Higashi Medical Center, Koga, Japan
Abstract : BACKGROUND. Both serum elevation of C-reactive protein (CRP) and reduction of lymphocyte in 
the peripheral blood has been known as indicator for malignant potential of human tumors. METHODS. Whether 
newly devised CLS (CRP/Lymphocyte Score), based on combined data of serum elevation of CRP and of lym-
phocyte percentage in the peripheral blood can be an indicator for progressive potential in colorectal carcinoma 
was examined in 280 cases who had been surgically treated. RESULTS. Significant difference in survival was 
observed both between CLS 0 and 1 and between CLS 1 and 2, in both cases when analyzed among whole pa-
tients and patient who had been treated with curative resection. Multivariate analysis among patients who 
had been treated with curative resection demonstrated that CLS (P < 0.0001), histologic type (P = 0.0003), and 
tumor stage (P = 0.039) were factors independently associated with worse prognosis of the patients. CONCLU-
SIONS. Newly devised criteria CLS could be an independent prognostic indicator in colorectal carcinoma and 
would be utilized as a helpful information. J. Med. Invest. 66 : 264-268, August, 2019
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INTRODUCTION
 
Serum elevation of C-reactive protein has been known as an 
indicator for aggressiveness of the tumor and/or patients’ prog-
nosis in malignant tumors of the digestive tracts such as gastric 
carcinoma (1) and esophageal carcinoma (2) as well as colorectal 
carcinoma (3, 4).
Decrease in lymphocyte in peripheral blood has been also 
reported to be correlated with malignant potential in colorectal 
carcinoma (5).
However, criteria based on the combined data of serum eleva-
tion of CRP and decrease in lymphocyte in peripheral blood in 
human tumors has not been presented.
In this study, we attempted to form a new scoring system to 
determine outcome of the patients with colorectal carcinoma 
based on combination of serum elevation of C-reactive protein 
and decrease in lymphocyte in peripheral blood.
PATIENTS AND METHODS
 
 Patients, collection of blood samples, and measurement of C-reactive 
protein (CRP) and lymphocyte percentage in peripheral blood. Two hun-
dred and eighty patients, composed of 165 men and 115 women, 
with colorectal carcinoma, which had been treated by surgical 
resection in our institute from 2004 to 2013, were enrolled in 
this study.
This study was approved by the institutional ethic committee 
of Fukuoka Higashi Medical Center.
Patients who have been suffering from other malignant 
tumors or other inflammatory diseases possibly causing the 
serum elevation of CRP were excluded from this study. Moreover 
there was no patients who had been treated with neoadjuvant 
therapy.
All blood samples to measure serum value of CRP were col-
lected just before the operation. Patients who had the serum 
concentration of more than 1.0 mg/dL, as applied in our series 
of investigations (1-3), were regarded to have a serum elevation 
of CRP. And among Japanese, the normal range of lymphocyte 
percentage in peripheral blood has been described as 21.2-51.0% 
in male and 21.3-50.2% in female in Kanai’s Manual of Clini-
cal Laboratory Medicine widely utilized in most institution in 
Japan. Then. lymphocyte percentage in the peripheral blood of 
less than 20% were regarded to have a decrease in lymphocyte.
Pathologic investigation. Pathologic investigation was performed 
using TNM classification of malignant tumors prescribed by the 
International Union Against Cancer (6).
Definition of CLS (CRP/Lymphocyte Score). Patients who had 
both serum elevation of CRP and decrease in lymphocyte were 
allocated a CLS of 2. Patients who had each one and neither were 
allocated a CLS of 1 and 0, respectively (Table 1). 
Follow-up of the Patients. The follow-up for patients was contin-
ued until their death and only patients who died of colorectal 
carcinoma were included in the tumor-related deaths. The period 
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Table 1.　Chart to calculate CLS
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from the operation to the date of death was defined to be the sur-
vival time. The survival time ranged from one month to 8 years 
and 6 months with a mean of 3 years and 6 months.
Statistical Analysis. All statistical analyses were performed 
using StatView (SAS Institute Inc, Cary, NC). Chi-square 
test and t test were used to compare the difference regarding 
values in each CLS score. Survival curves were made by the 
Kaplan-Meier method, and the Mantel-Cox test was used to 
analyze the equality of the survival curves. Cox proportional 
hazards model in a forward stepwise manner was used to 
perform a multivariate analysis to determine the independent 
prognosticators. A P value of less than 0.05 was considered to 
demonstrate a significant difference.
RESULTS
 
Correlation of the CLS with clinicopathologic features was 
shown in Table 2. Significant difference was observed regarding 
depth of tumor (P = 0.003), stage of the tumor (P = 0.0053), and 
similarly, the rate of curative resection (P = 0.021). 
The survival of CLS 1 patients with 5-year survival rate of 
73.3% was significantly more unfavorable than that of CLS 
0 patients with 5-year survival rate of 90.8% (P = 0.003). Prog-
nosis of CLS 2 patients with 5-year survival rate of 43.2% was 
significantly worse than that of TRHRS 1 patients (P = 0.015, 
Fig. 1). 
An analysis restricted to patients who had been treated with 









      Male 105 (59.0)  33 (52.4) 27 (69.2) 0.243
      Female  73 (41.0)  30 (47.6) 12 (30.8)
Age 69.6 ± 11.7 70.8 ± 10.9 71.0 ± 9.2 0.477
Location of tumor
      Colon 122 (68.5)  46 (73.0) 33 (84.6) 0.126
      Rectum  56 (31.5)  17 (27.0)  6 (15.4)
Depth of tumor
      T1, 2  62 (34.8)  12 (19.0)  4 (10.3) 0.0005
      T3, 4 114 (65.2)  51 (81.0) 35 (89.7)
Histology*
      Well  58 (32.6)  15 (23.8) 10 (25.6) 0.127
      Moderately 109 (61.2)  41 (65.1) 26 (66.7)
      Poorly  11 (  6.2)   7 (11.1)  3 (  7.7)
Nodal metastasis
      No 103 (57.9)  39 (61.9) 18 (46.2) 0.083
      Yes  75 (42.1)  24 (38.1) 21 (53.8) 
Lymphatic invasion
      No 105 (59.0)  39 (61.9) 17 (43.6) 0.153
      Yes  73 (41.0)  24 (38.1) 22 (56.4)
Venous invasion
      No 133 (74.7)  50 (79.4) 28 (71.8) 0.654
      Yes  45 (25.3)  13 (20.6) 11 (28.2)
Tumor stage
      I  57 (32.0)  12 (19.1)  2 (  5.2) 0.0053
      II  45 (25.3)  21 (33.3) 14 (35.9)
      III  67 (37.6)  25 (39.7) 16 (41.0)
      IV   9 (  5.1)   5 (  7.9)  7 (17.9)
Curability for resection
      Curative 169 (94.9)  58 (92.1) 32 (82.1) 0.021
      Non-curative   9 (  5.1)   5 (  7.9)  7 (17.9)
CLS, CRP/Lymphocyte Score
Values in the parenthesis are the percentages.
*Well, well differentiated adenocarcinoma ; Moderately, moderately differentiated adenocarcinoma ; Poorly, 
pooyly differentiated adenocarcinoma;
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curative resection was additionally done (Table 3). A significant 
difference was observed regarding depth of tumor (P = 0.003) 
and stage of the tumor (P = 0.013).
The survival of CLS 1 patients with 5-year survival rate of 
75.3% was significantly more unfavorable than that of CLS 0 pa-
tients with 5-year survival rate of 93.6% (P = 0.002). Prognosis 
of CLS 2 patients with 5-year survival rate of 45.2% was signifi-
cantly worse than that of CLS 1 patients (P = 0.030, Fig. 2).
In univariate analysis among patients who had been treated 
with curative resection, CLS (P < 0.0001), lymphatic invasion 
(P = 0.0005), venous invasion (P = 0.038), histologic type (P < 
0.0001) and tumor stage (P = 0.0004) were factors possibly to 
determine patients’ prognosis. Multivariate analysis including 
all these factors demonstrated that CLS (P < 0.0001) as well as 
histologic type (P = 0.0003) and tumor stage (P = 0.039) were 
found to be factors independently associated with worse progno-
sis of the patients (Table 4).
Fig. 1.　CLS and survival curves among whole patients.
Significant difference was observed between survival of CLS 0 and 1 
patients (P = 0.030) and between survival of CLS 1 and 2 patients (P 
= 0.015).










      Male 103 (60.9)  31 (53.4) 21 (65.6) 0.468
      Female  66 (39.1)  27 (46.6) 11 (34.4)
Age 70.0 ± 11.8  70.5 ± 11.2 72.0 ± 8.1 0.204
Location of tumor
      Colon 119 (70.4)  43 (74.1) 27 (84.4) 0.258
      Rectum  50 (29.6)  15 (25.9)  5 (15.6)
Depth of tumor
      T1, 2  62 (36.7)  12 (20.7)  4 (12.5) 0.005
      T3, 4 107 (63.3)  46 (79.3) 28 (87.5)
Histology*
      Well  56 (33.1)  15 (25.9)  9 (28.1) 0.679
      Moderately  103 (61.0)  37 (63.8) 20 (62.5)
      Undifferentiated  10 (  5.9)   6 (10.3)  3 (  9.4)
Nodal metastasis
      No 102 (60.4)  33 (56.9) 16 (50.0) 0.536
      Yes  67 (39.6)  25 (43.1) 16 (50.0) 
Lymphatic invasion
      No 102 (60.4)  36 (62.1) 14 (43.8) 0.182
      Yes  67 (39.6)  22 (37.9) 18 (56.2)
Venous invasion
      No 130 (76.9)  48 (82.8) 24 (75.0) 0.592
      Yes  39 (23.1)  10 (17.2)  8 (25.0)
Tumor stage
      I  57 (33.7)  12 (20.7)  2 (  6.2) 0.013
      II  45 (26.6)  21 (36.2) 14 (43.8)
      III  67 (39.7)  25 (43.1) 16 (50.0)
CLS, CRP/Lymphocyte Score
Values in the parenthesis are the percentages.
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DISCUSSION
Serum elevation of C-reactive protein, an acute phase protein, 
has been known as a definitive indicator for aggressiveness 
of the tumor and/or patients’ prognosis in malignant tumors 
including colorectal carcinoma (3, 4). Also other than the individ-
ual significance of serum elevation of CRP, cumulative scoring 
system, namely Glasgow prognostic score that can be construct-
ed by serum elevation of CRP and hypoalbuminemia, has been 
demonstrated to stratify prognosis of patients with colorectal 
carcinoma (7-10). Moreover prognostic nutritional index con-
structed by the value of serum albumin and lymphocyte counts 
in the peripheral blood has been emphasized to be a prognostic 
indicator of colorectal carcinoma (11).
On the other hand, decrease in lymphocyte in the peripheral 
blood has been reported also to be an indicator to predict worse 
prognosis of patients with colorectal carcinoma (12). 
A significant correlation between serum elevation of CRP and 
decrease in lymphocyte in the peripheral blood was found in this 
study, which is concomitant with the result reported in the pre-
vious investigation (13). Immunosuppressive condition of the tu-
mor-bearing patients might cause both decrease in lymphocyte 
in the peripheral blood and serum elevation of CRP. 
These findings promoted us to possibly construct a new cri-
teria to determine a malignant potential and/or prognosis of 
patients with colorectal carcinoma based on the two elements, 
serum elevation of CRP and decrease in lymphocyte in peripher-
al blood, which similarly influence the prognosis of the patients 
with colorectal carcinoma.
Significant correlation between CLS and curability was ob-
served, which could demonstrate an utility of CLS as an in-
dicator for malignant potential of the tumor and preoperative 
predictor for possible curative resection of colorectal carcinoma.
Moreover, in this study, indeed, a significant correlation was 
found between CLS and an incidence of non-curative resection 
due to the co-existence of distant metastasis or peritoneal dis-
semination. Suppressed physical condition caused by the cachex-
ia derived from far advanced carcinoma with distant metastasis 
could influence the both the values of serum level of CRP and 
lymphocyte ratio in the peripheral blood. Therefore, analysis 
restricted to the cases who had been treated with curative resec-
tion was additionally done and nevertheless the significance of 
CLS as an independent prognostic indicator in colorectal carci-
noma was elucidated. 
Incidentally, also from the multivariate analysis in the current 
study, pathological incidence of poorly differentiated colorectal 
carcinoma could contain more progressive potential, as having 
been reported in the previous study (4, 14).
In conclusion, this newly devised simple and convenient cri-
teria, CLS, can be measured using a basic examinations would 
strictly classify the prognosis in colorectal carcinoma and would 
provide a beneficial information regarding the clinical course of 
patients with colorectal carcinoma.
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